Citius Pharmaceuticals Announces 2026 Annual Stockholder Meeting Results

Citius Pharmaceuticals ( (CTXR) ) has issued an announcement.

On April 6, 2026, Citius Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders, at which shareholders elected seven directors, including Leonard Mazur, Myron Holubiak, Suren Dutia, Dr. Eugene Holuka, Dennis M. McGrath, Robert Smith, and Carol Webb, to one-year terms expiring at the 2027 annual meeting. Shareholders also ratified the appointment of Wolf & Company, P.C. as the company’s independent registered public accounting firm for the fiscal year ending September 30, 2026, reinforcing continuity in governance and external financial oversight for the biopharmaceutical developer.

The most recent analyst rating on (CTXR) stock is a Hold with a $0.67 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Spark’s Take on CTXR Stock

According to Spark, TipRanks’ AI Analyst, CTXR is a Neutral.

The score is held back primarily by large ongoing losses and significant cash burn, reinforced by weak technical momentum. Offsetting factors include a low-debt balance sheet and positive LYMPHIR-related corporate updates indicating early commercial traction and encouraging Phase 1 signals, but valuation support is limited given negative earnings.

To see Spark’s full report on CTXR stock, click here.

More about Citius Pharmaceuticals

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing critical care and cancer care products. The company operates in the biopharmaceutical sector, targeting unmet medical needs through proprietary formulations and late-stage product candidates aimed at hospital and oncology markets.

Average Trading Volume: 554,789

Technical Sentiment Signal: Strong Sell

Current Market Cap: $19.11M

For an in-depth examination of CTXR stock, go to TipRanks’ Overview page.